BCL2 and B-cell chronic lymphocytic leukemia: Some small molecule inhibitors of BCL2 family were also reported as entering clinical trials, such as ABT-263/navitoclax, or approved for the treatment of chronic lymphocytic leukemia like ABT-199/venetoclax, due to its BCL2 specificity and low toxicity [21].